Press Releases ALX Oncology Holdings Inc.

Equities

ALXO

US00166B1052

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-01 EDT			5-day change	1st Jan Change
16.94 ^USD	-0.47%		+4.44%	+13.77%

04-30	ALX Oncology Holdings Inc. Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer	CI
04-18	Alx Oncology Holdings Insider Sold Shares Worth $710,195, According to a Recent SEC Filing	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer	04-30	GL
ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer	04-30	AQ
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting	04-24	GL
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)	04-09	GL
ALX Oncology : Corporate Presentation	03-11	PU
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	03-07	GL
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting	03-05	GL
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting	03-05	AQ
ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference	01-03	GL
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update	11-13	GL
ALX Oncology Announces November Investor Conference Participation	11-01	GL
ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares	23-10-10	GL
ALX Oncology Announces Pricing of Public Offering	23-10-05	GL
ALX Oncology Announces Pricing of Public Offering	23-10-05	AQ
ALX Oncology Announces Proposed Public Offering	23-10-04	GL
ALX Oncology : ASPEN-06 Phase 2 Interim Gastric/GEJ Cancer Data Conference Call	23-10-03	PU
ALX Oncology : Corporate Presentation	23-10-03	PU
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer	23-10-03	GL
ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer	23-10-02	GL
ALX Oncology : Corporate Presentation	23-09-25	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases ALX Oncology Holdings Inc.

Equities

ALXO

US00166B1052

Press Releases

Filters